| Attributes | Values |
|---|
| rdf:type
| |
| http://linked.open...gbank/description
| - Tumor necrosis factor (TNF-alpha) binding antibody (chimeric IgG1). It is composed of human constant and murine variable regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion (en)
|
| http://linked.open...y/drugbank/dosage
| |
| http://linked.open...generalReferences
| - # Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P, et al.: Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993 Nov;30(16):1443-53. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8232330 #American Society of Health System Pharmacists, Inc., DynaMed [Internet]. Ipswich (MA): EBSCO Information Services. 1995. Infliximab; [updated 2014 Aug 27; cited 2014 Nov 12]. Available fromhttp://web.b.ebscohost.com/dynamed/detail?vid=15&sid=c9ea9657-342a-4b9b-a3bb-bf363d5d58c4%40sessionmgr112&hid=110&bdata=JnNpdGU9ZHluYW1lZC1saXZlJnNjb3BlPXNpdGU%3d#db=dme&AN=232803&anchor=Mechanism-of-Action-Pharmacokinetics # Dubinsky MC, Fleshner PP: Treatment of Crohn's Disease of Inflammatory, Stenotic, and Fistulizing Phenotypes. Curr Treat Options Gastroenterol. 2003 Jun;6(3):183-200. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12744819 # Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ: Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999 May 6;340(18):1398-405. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10228190 # Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ: Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004 Feb 26;350(9):876-85. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14985485 # Hanauer SB: Crohn's disease: step up or top down therapy. Best Pract Res Clin Gastroenterol. 2003 Feb;17(1):131-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12617888 # http://www.google.co.in/patents/US8524217 #Lexicomp Online (2014). Infliximab Available at: http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7084#f_pharmacology-and-pharmacokinetics [Accessed 12 Nov. 2014]. (en)
|
| http://linked.open...gy/drugbank/group
| |
| http://linked.open...drugbank/halfLife
| - 9.5 days (7-12 days) in patients with Crohn's disease, plaque psoriasis and rheumatoid arthritis (en)
|
| http://linked.open...ugbank/indication
| - To manage the signs and symptoms, as well as to induce and maintain clinical remission in adults with moderate to severe active Crohn's disease or ulcerative colitis. Also used to manage signs and symptoms of rheumatoid arthritis (in conjunction with methotrexate), ankylosing spondylitis, psoriatic arthritis, and juvenile arthritis. (en)
|
| http://linked.open...bank/manufacturer
| |
| sameAs
| |
| Title
| |
| adms:identifier
| |
| http://linked.open...mechanismOfAction
| - Infliximab neutralizes the biological activity of TNFa by binding with high affinity to the soluble and transmembrane forms of TNFa and inhibits binding of TNFa with its receptors. Infliximab does not neutralize TNFb (lymphotoxin a), a related cytokine that utilizes the same receptors as TNFa. TNFa activation normally induces the release of proinflammatory cytokines, the enhancement of leukocyte migration and activation of neutrophils among others. Neutralization of the biological activity of TNFa leads to an overall reduction in inflammation. (en)
|
| http://linked.open...drugbank/packager
| |
| http://linked.open...y/drugbank/patent
| |
| http://linked.open.../drugbank/synonym
| - Ig gamma-1 chain C region (en)
|
| http://linked.open...umeOfDistribution
| |
| http://linked.open.../drug/hasAHFSCode
| |
| foaf:page
| |
| http://linked.open...Molecular-Formula
| |
| http://linked.open.../Molecular-Weight
| |
| http://linked.open...l/drug/hasATCCode
| |
| http://linked.open...ugbank/absorption
| - Onset of action occurs in about 2 weeks in Crohn's disease. (en)
|
| http://linked.open.../affectedOrganism
| - Humans and other mammals (en)
|
| http://linked.open...casRegistryNumber
| |
| http://linked.open...drugbank/category
| |
| http://linked.open...gbank/containedIn
| |
| http://linked.open...nk/Hydrophobicity
| |
| http://linked.open...Isoelectric-Point
| |
| http://linked.open...ank/Melting-Point
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)